Inhibikase Therapeutics FY 2024 GAAP EPS $(1.16) Misses $(0.90) Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings MissesNews
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.90) by 28.89 percent. This is a 63.29 percent increase over losses of $(3.16) per
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.90) by 28.89 percent. This is a 63.29 percent increase over losses of $(3.16) per share from the same period last year.